Login / Signup

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Elias Karl MaiThomas HielscherUta BertschJana SchlenzkaHans J SalwenderMarkus MunderChristian GereckeUlrich DührsenPeter BrossartKai NebenJens HillengassMarc S RaabMaximilian MerzMarc-Andrea BaertschAnna JauchDirk HoseHans MartinHans-Walter LindemannIgor W BlauChristof ScheidKatja C WeiselHartmut Goldschmidtnull null
Published in: Leukemia (2018)
Keyphrases
  • low dose
  • newly diagnosed
  • multiple myeloma
  • high dose
  • stem cells